Iron Overload Treatment

Deferasirox (ASUNRA) Tablet

$60.00 – $83.00

Vigilant monitoring of these parameters throughout the treatment course ensures both safety and efficacy. Furthermore, patients receive guidance on dietary and lifestyle modifications aimed at optimizing iron overload management and overall well-being.

Strength	Choose an option100mg400mg
	Clear

Quantity

Deferasirox (ASUNRA) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Deferasirox ASUNRA

Description

Deferasirox (ASUNRA) 100mg Tablet is an oral iron chelator used in the treatment of chronic iron overload due to blood transfusions in patients with certain hematological disorders, such as beta-thalassemia and other transfusion-dependent anemias. It helps to remove excess iron from the body by binding to it and promoting its excretion through urine and feces.

Key Features:

• Iron Chelation Therapy: Deferasirox acts as an iron chelator, binding to excess iron in the body and forming stable complexes that are then excreted via urine and feces. By removing excess iron, it helps to prevent iron overload, which can lead to organ damage and other complications in patients receiving chronic blood transfusions.
• Treatment of Iron Overload: Deferasirox (ASUNRA) 100mg Tablet is indicated for the treatment of chronic iron overload due to blood transfusions in patients with beta-thalassemia and other transfusion-dependent anemias. It offers a targeted treatment option for managing iron overload and its associated complications.
• Oral Administration: Deferasirox (ASUNRA) 100mg Tablet is administered orally, typically once daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Dose Adjustments: The dose of deferasirox may need to be adjusted based on factors such as the patient’s serum ferritin levels, transfusion requirements, and tolerability. Regular monitoring of serum ferritin levels and other parameters is necessary to assess treatment response and adjust the dose accordingly.
• Efficacy: Clinical studies have demonstrated the efficacy of deferasirox in reducing serum ferritin levels and liver iron concentration in patients with transfusion-dependent anemias. It has shown comparable efficacy to other iron chelators with a more convenient dosing regimen and improved tolerability.
• Safety Profile: Deferasirox generally has a manageable safety profile when used as directed. However, like all medications, it may be associated with certain side effects, including gastrointestinal disturbances (e.g., nausea, vomiting, abdominal pain), skin rash, and renal impairment. Patients should be closely monitored for adverse reactions during treatment.
• Patient Education: Patients prescribed Deferasirox (ASUNRA) 100mg Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated about the signs and symptoms of iron overload and the importance of regular monitoring.
• Consultation with Healthcare Provider: Treatment with Deferasirox (ASUNRA) 100mg Tablet should be initiated and monitored by a qualified hematologist or healthcare provider experienced in the management of iron overload disorders. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Deferasirox (ASUNRA) 100mg Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective iron chelation therapy is crucial for preventing complications associated with iron overload in patients with transfusion-dependent anemias.

Additional information